DPV 001

Drug Profile

DPV 001

Alternative Names: Autologous DRibble vaccine; Cancer vaccine DRibble; DRibble Vaccine

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UbiVac
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 02 Jun 2017 Efficacy data from a phase II trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 UbiVac plans a phase Ib/II trial in Prostate cancer (Combination therapy, Late stage disease) and Breast cancer (Combination therapy)
  • 01 Apr 2017 UbiVac completes a phase II trial in Non-small cell lung cancer (Combination therapy, Late stage disease) in USA (NCT01909752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top